Sintetica US launches Lidocaine Hydrochloride Injection, USP 1%, 2% and 4%

2023-03-27

上市批准

Lidocaine hydrochloride is a short-acting amide-type local anesthetic with a rapid onset and short duration of action and contains no preservatives. MENDRISIO, Switzerland and PRINCETON, N.J, March 27, 2023 /PRNewswire/ -- Sintetica S.A., an international pharmaceutical company with manufacturing facilities in Switzerland, announces the launch of Lidocaine Hydrochloride Injection, USP 1%, 2% and 4% through its subsidiary Sintetica US. Sintetica's unique ability to produce sterile injectable drugs has enabled it to establish strong business relationships in the US, with a track record of over ten years of providing high-quality products, earning a solid reputation and the trust of partners and healthcare professionals. Now Sintetica reaches an important milestone in the US with its Lidocaine Injection product launched through Sintetica US, our new entity established in 2022 in Princeton, New Jersey. With this product Sintetica US will be able to support healthcare professionals who are facing a difficult situation due to the critical shortage of this product. Sintetica is now positioned to have a direct presence in the US through Sintetica US and support this important market, while also consolidating its presence by expanding its highly attractive portfolio with innovative products suitable for the US market. Frank Mullery, President of Sintetica US, said: "Sintetica is excited to announce the launch of Lidocaine Hydrochloride Injection, the first commercial launch for Sintetica US. Most importantly, we are bringing the product to market during a critical shortage, with our ability to produce large volumes of Lidocaine we will provide access to this important product when it's needed most. This milestone represents the first of many expected product launches for Sintetica US and is a great accomplishment of the entire global Sintetica team". Nicola Caronzolo, Sintetica Chief Executive Officer, added: "I'm particularly proud of this significant step in the 100-year history of Sintetica, which is increasingly establishing itself in international markets thanks to the quality of its products and the reliability of its services. I would like to take this opportunity to thank the many people involved who make our success story possible every day". About Lidocaine View the original content with multimedia: Important safety information 1% and 2% and Full Prescribing Information: Important safety information 4% and Full Prescribing Information: About Sintetica Based in Switzerland, Sintetica is a privately held international pharmaceutical company focused on emergency and intensive care, analgesics, local anesthetics and sterile injectable solutions in ampules, vials and IV bags for hospitals. Sintetica develops medicines in concentrated and ready-to-use (Premixed) formulations, which enables healthcare practitioners to administer these products without further manipulation and dilution, increasing patient safety and improving convenience for patients and HCPs. Sintetica runs sales subsidiaries in selected European markets and partners with leading distributors around the world. For more information about Sintetica S.A.: For more information about Sintetica US: . Contacts For sales opportunities, contracting, and product availability: contactus@sintetica.com Business Development: bdus@sintetica.com Media: Daniele Fontana Sustainability&HR Corporate Director communications@sintetica.com +41 79 218 90 57 Photo - Logo -

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构